Results 11 to 20 of about 23,495,426 (286)

Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. [PDF]

Nature Communications, 2018
Lipoprotein(a), Lp(a), is a modified low-density lipoprotein particle that contains apolipoprotein(a), encoded by LPA, and is a highly heritable, causal risk factor for cardiovascular diseases that varies in concentrations across ancestries. Here, we use
Alver, Maris, Bloom, Jonathan, Budoff, Matthew, Chaffin, Mark, Correa, Adolfo, Cupples, L Adrienne, Daly, Mark J, Engreitz, Jesse, Ernst, Jason, Esko, Tonu, Fu, Mao, Ganna, Andrea, Handsaker, Robert E, Johnson, W Craig, Kathiresan, Sekar, Kellis, Manolis, Manichaikul, Ani, McCarroll, Steven, Metspalu, Andres, Mitchell, Braxton D, Natarajan, Pradeep, Neale, Benjamin M, NHLBI TOPMed Lipids Working Group, Peloso, Gina M, Post, Wendy, Poterba, Timothy, Rich, Stephen S, Ripatti, Samuli, Rotter, Jerome I, Ruotsalainen, Sanni, Ryan, Kathleen A, Salomaa, Veikko, Seed, Cotton, Surakka, Ida, Tsai, Michael, Vasan, Ramachandran S, Wilson, James G, Yang, Chaojie, Zekavat, Seyedeh M   +38 more
core   +2 more sources

Lipoprotein(a) [PDF]

Clinical Research in Cardiology Supplements, 2019
Lipoprotein(a) (LP(a))—discovered by Kare Berg [1] in 1963—is of increasing importance in clinical routine as reflected by the ESC/EAS Guidelines for the Management of Dyslipidaemias and the recent AHA Guideline [2, 3].
K P, Mellwig, A, Vogt
openaire   +3 more sources

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance Epidemiological and genetic data have implicated lipoprotein(a) as a potentially modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no approved pharmacological treatments.
Steven E. Nissen, Helle Linnebjerg, Xi Shen, K. Wolski, Xiaosu Ma, Shufen Lim, Laura F Michael, Giacomo Ruotolo, Grace Gribble, A. Navar, Stephen J. Nicholls   +10 more
semanticscholar   +1 more source

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment

Molecules, 2023
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely
S. Lampsas, Maria Xenou, E. Oikonomou, Panteleimon Pantelidis, A. Lysandrou, S. Sarantos, A. Goliopoulou, K. Kalogeras, V. Tsigkou, Athanasios Kalpis, S. Paschou, P. Theofilis, M. Vavuranakis, D. Tousoulis, G. Siasos   +14 more
semanticscholar   +1 more source

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

New England Journal of Medicine, 2022
BACKGROUND Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. METHODS We conducted a randomized, double-blind, placebo-controlled,
M. O’Donoghue, R. Rosenson, B. Gencer, J. A. López, N. Lepor, S. Baum, Elmer Stout, D. Gaudet, B. Knusel, J. Kuder, Xinhui Ran, S. Murphy, Hong Wang, You Wu, H. Kassahun, M. Sabatine   +15 more
semanticscholar   +1 more source

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Arteriosclerosis, Thrombosis and Vascular Biology, 2021
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lp(a)
G. Reyes-Soffer, H. Ginsberg, L. Berglund, P. Duell, S. Heffron, P. Kamstrup, D. Lloyd‐Jones, S. Marcovina, C. Yeang, M. Koschinsky   +9 more
semanticscholar   +1 more source

D Vitamini Eksikliği Olan Yetişkinlerde Paraoksonaz ve Arilesteraz Aktiviteleri

Sakarya Tıp Dergisi, 2021
Amaç: Bu çalışmanın amacı, D vitamini eksikliği olan erişkinlerde Paroksonaz (PON) ve Arilesteraz (ARE) enzim aktivitelerini araştırmak, D vitamini eksikliğinin oksidatif stres ve kardiyovasküler hastalıklar için risk belirteci olan PON-1, ARE ve Lp (a ...
Filiz Alkan Baylan, Metin Kılınç, Hatice Sağer, Yeliz Doboğlu   +3 more
doaj   +1 more source

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

New England Journal of Medicine, 2020
BACKGROUND Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.
S. Tsimikas, E. Karwatowska-Prokopczuk, I. Gouni-Berthold, J. Tardif, S. Baum, E. Steinhagen-Thiessen, M. Shapiro, E. Stroes, P. Moriarty, B. Nordestgaard, S. Xia, Jonathan Guerriero, N. Viney, L. O’Dea, J. Witztum   +14 more
semanticscholar   +1 more source

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease

Arteriosclerosis, Thrombosis and Vascular Biology, 2020
Supplemental Digital Content is available in the text. Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In
A. Patel, Minxian Wang, J. Pirruccello, P. Ellinor, Kenney Ng, S. Kathiresan, A. Khera   +6 more
semanticscholar   +1 more source

Statin therapy increases lipoprotein(a) levels.

European Heart Journal, 2020
AIMS Lipoprotein(a) [Lp(a)] is elevated in 20-30% of people. This study aimed to assess the effect of statins on Lp(a) levels. METHODS AND RESULTS This subject-level meta-analysis includes 5256 patients (1371 on placebo and 3885 on statin) from six ...
S. Tsimikas, P. Gordts, Chelsea L. Nora, C. Yeang, J. Witztum   +4 more
semanticscholar   +1 more source